logo
Here's why you feel awful after going back to bed for that extra hour of sleep

Here's why you feel awful after going back to bed for that extra hour of sleep

Yahoo15-06-2025

If you've woken up way too early for no good reason, going back to bed for that extra hour of sleep may not be as beneficial as you'd hoped.
Instead, you're better off just staying awake, because slipping back into sleep will leave you feeling groggy and agitated since you've disturbed your 90-minute sleep cycle.
'If you were to sleep till you woke up naturally, often, you'd be fine because you'd be in the natural cycle. But then, when you fall asleep and then your alarm wakes you up … you have a good chance of ending up awakening in a deeper sleep phase when you weren't meant to wake up,' Dr. Greg Mahr, a psychiatrist at Henry Ford Health, told The Independent. 'You feel really groggy because you haven't gone through the natural rhythm.'
Changes in the brain are 'fairly clear,' he said, looking at recordings of brain activity.
When you interrupt those deeper stages of sleep, it can take a while to recover, whereas, being woken up in other lighter stages of sleep does not yield the same results. This is true even if you technically get enough sleep.
'It's typically not listening to our body cycles and trying to override them because of our schedules and alarm clocks,' Mahr noted.
Alarm clocks can play a major role in sleep health. Recent research has found that more than 50 percent of 3 million sleep sessions studied ended in a 'snooze.' People spent an average of 11 minutes between snooze alarms before waking and heavy snoozers averaged 20 minutes a day, according to Dr. Rebecca Robbins, a sleep scientist at Brigham and Women's Hospital and assistant professor at Harvard Medical School.
'Unfortunately, the snooze alarm disrupts some of the most important stages of sleep. The hours just before waking are rich in rapid eye movement sleep. Hitting the snooze alarm will interrupt these critical stages of sleep and typically only offer you light sleep in between snooze alarms,' she explained.
How many alarms you set can also be a red flag, according to Johns Hopkins Medicine Dr. Rachel Salas.
'If you're a 10-alarm person, that is a huge red flag. If you have to hit the snooze button and you're not waking up, that's a red flag that something may be going on while you're sleeping that you're not aware of,' she explained. 'You might have an undiagnosed, untreated sleep disorder.'
People might not be able to control their variable work schedules or environmental conditions. But, can they hack the system? Can you sneak a little extra sleep in without feeling the effects? Salas says you can.
'Taking a nap before 3 p.m. for less than an hour – ideally, 20 or 30 minutes – that's one way to pay back and not affect the other process that's important for sleep that runs with the circadian rhythm. It's called the homeostatic drive,' she said. Otherwise, you can get yourself in a vicious cycle of bad sleep.
But there's one way to ensure you're waking up as fresh as can be.
'The best approach for optimizing your sleep and next day performance is to set your alarm for the latest possible time, then commit to getting out of bed when your first alarm goes off,' Robbins said.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Goldman Sachs Reaffirms 'Buy' Rating on Iovance (IOVA) for Positive Amtagvi Data
Goldman Sachs Reaffirms 'Buy' Rating on Iovance (IOVA) for Positive Amtagvi Data

Yahoo

time36 minutes ago

  • Yahoo

Goldman Sachs Reaffirms 'Buy' Rating on Iovance (IOVA) for Positive Amtagvi Data

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the 10 best healthcare penny stocks to buy according to analysts. Goldman Sachs reiterated its 'Buy' rating on Iovance's stock on June 3. The firm also maintained its $34.00 price target for Iovance shares. A close up of a lab technician in a protective suit, working with cells in a petri dish to develop innovative therapeutics for immune-related diseases. Goldman Sachs based its reaffirmation on new data that Iovance presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO data focused on Amtagvi, a tumor-infiltrating lymphocyte (TIL) therapy. The FDA approved the treatment in February 2024 for adult patients with unresectable or metastatic melanoma. The data supported the therapy's safety profile, which, according to Goldman Sachs, reinforces Amtagvi's potential as a significant treatment option. Goldman Sachs's analysts noted that the five-year follow-up data are unprecedented for any therapy in this heavily pretreated advanced melanoma population. To them, the data highlights the durability of Amtagvi's responses. The firm emphasized Amtagvi's successful US launch, with consistent patient demand, enhanced operations at Authorized Treatment Centers (ATCs), and improved out-of-spec rates (manufacturing quality metrics). It also highlighted the drug's first full calendar year of sales in 2025 as a key driver. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a commercial-stage biopharmaceutical company. It develops and markets cell therapies that harness a patient's own immune cells to treat solid tumors. Its lead product is Amtagvi, approved for advanced melanoma, and it also markets Proleukin. Iovance's pipeline includes candidates for cervical cancer, non-small cell lung cancer, and hematologic malignancies. While we acknowledge the potential of IOVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Akebia Therapeutics (AKBA) Grants Stock Options to New Employees
Akebia Therapeutics (AKBA) Grants Stock Options to New Employees

Yahoo

time36 minutes ago

  • Yahoo

Akebia Therapeutics (AKBA) Grants Stock Options to New Employees

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 2, the company reported that it had granted options to purchase an aggregate of 137,000 shares of its common stock to three newly hired employees on May 30, 2025. yezry/ These options were given as inducement material to each employee entering into employment with Akebia. The company stated that the grants were made per Nasdaq Listing Rule 5635(c)(4). Also, the exercise price for the options is $3.03 per share, which was the closing price of the company's common stock on the grant date. The stock options vest over a four-year period, with 25% of the shares vesting on the first anniversary of the grant date. The remaining 75% will vest quarterly thereafter, provided the new employee remains with Akebia. The options are the latest after Akebia granted 148,000 shares of its common stock to eight newly hired employees on April 30, 2025. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company focused on developing treatments for kidney-related diseases. It develops and sells two main products: Auryxia, used to manage phosphorus levels and treat iron deficiency anemia in patients with chronic kidney disease (CKD), and Vafseo, an oral medication for anemia associated with CKD. While we acknowledge the potential of AKBA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Maravai LifeSciences (MRVI) Undergoes Leadership Overhaul Amid Transition
Maravai LifeSciences (MRVI) Undergoes Leadership Overhaul Amid Transition

Yahoo

time36 minutes ago

  • Yahoo

Maravai LifeSciences (MRVI) Undergoes Leadership Overhaul Amid Transition

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 26, William Blair reaffirmed its 'Market Perform' rating for Maravai stock. The key factor influencing this move is the leadership changes at Maravai. A scientist performing a blood test on a patient using life sciences tools & services. Maravai has undergone a complete leadership overhaul since December last year. In December 2024, the company brought in Andy Eckert as the new independent Chairman of the Board. Later, Maravai installed Bernd Brust as CEO, replacing Trey Martin. Then, on June 25, a new press release indicated that Rajesh 'Raj' Asarpota would assume the position of Executive Vice President and Chief Financial Officer, effective June 30. According to William Blair, Brust and Asarpota are joining Maravai's top-level management when the company is undergoing 'a challenging operational transition period.' The analysts noted that the company 'faces approximately $66 million in headwinds in 2025 from declining COVID-related revenues.' As such, the analysts are optimistic that the fresh hands at Maravai's helm will inject more momentum into the transition. Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) is a life sciences company. It provides specialized products that support the development of vaccines, drug therapies, diagnostics, and cell and gene therapies. Its operations span two segments: Nucleic Acid Production and Biologics Safety Testing. While we acknowledge the potential of MRVI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store